ASCO: Adjuvant Breast Cancer Beckons for Merck/AZ’s Lynparza With OlympiA

A decent 42% reduction in the risk of recurrence in high-risk early-stage BRCA mutated disease should open another new market for the leading PARP inhibitor. Data also hint at a survival benefit to come.